ClinConnect ClinConnect Logo
Search / Trial NCT02617069

Botulinum Toxin Injection Into Epicardial Fat Pads to Prevent Atrial Fibrillation in Patients Undergoing Cardiac Surgery

Launched by MESHALKIN RESEARCH INSTITUTE OF PATHOLOGY OF CIRCULATION · Nov 27, 2015

Trial Information

Current as of May 02, 2025

Unknown status

Keywords

Atrial Fibrillation Botulinum Toxin

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Key inclusion Criteria:
  • Indication for cardiac surgery (e.g. coronary artery bypass grafting, valve repair/replacement) according to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines for cardiac surgery
  • Key exclusion Criteria:
  • Planned maze procedure or pulmonary vein isolation

About Meshalkin Research Institute Of Pathology Of Circulation

The Meshalkin Research Institute of Pathology of Circulation is a leading clinical research organization dedicated to advancing cardiovascular health through innovative research and development. Renowned for its commitment to scientific excellence, the institute specializes in studying the pathophysiology of circulatory diseases and developing novel therapeutic approaches. With a multidisciplinary team of experts, state-of-the-art facilities, and a robust infrastructure for clinical trials, the institute plays a pivotal role in translating research findings into practical solutions that enhance patient outcomes and contribute to the global understanding of cardiovascular conditions.

Locations

Novosibirsk, , Russian Federation

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials